Andere Sprachen Newron Pharmaceuticals S.p.A.

Aktien

A0LF18

IT0004147952

NWRN

Markt geschlossen - Swiss Exchange Andere Börsenplätze 17:31:59 30.04.2024			% 5 Tage	% 1. Jan.
8,21 ^CHF	+7,46 %		+14,35 %	+65,86 %

30.04.	Newron Pharmaceuticals S.p.A. gibt positive Ergebnisse der potenziell zulassungsrelevanten Phase II/III-Studie 008A mit Evenamide bei Schizophrenie-Patienten bekannt	CI
30.04.	Newron erzielt Forschungserfolg mit Schizophrenie-Hoffnungsträger	AW

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients	30.04.
Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients	30.04.
Newron: nouvelles données positives pour le médicament contre la schizophrénie	30.04.
Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients	30.04.
Feu vert généralisé à l'assemblée générale de Newron	17.04.
Newron Pharmaceuticals S p A : announces AGM 2024 results	17.04.
Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member	17.04.
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)	08.04.
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)	08.04.
Newron Pharmaceuticals S p A : Invitation to attend the General Meeting	27.03.
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	19.03.
Newron Presents 2023 Financial Results and Provides 2024 Outlook	19.03.
Newron dispose encore d'une année de réserves de liquidités	19.03.
Newron Pharmaceuticals' FY23 Loss Narrows; Revenue Up	19.03.
Newron presents 2023 financial results and provides 2024 outlook	19.03.
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement	15.03.
Newron Pharmaceuticals S.p.A. Announces Agreement with the European Investment Bank to Extend the Near-Term Tranche Repayment Dates of Its 2018 Financing Agreement	15.03.
Newron repousse le remboursement de paiements à la BEI	15.03.
Newron Pharmaceuticals Secures Extension on Three Loan Repayments	15.03.
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement	15.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Newron Pharmaceuticals S.p.A.

Aktien

A0LF18

IT0004147952

NWRN

Andere Sprachen

Filter